Inhibrx Biosciences (INBX) Filings

15-12G

Securities registration termination

10 Jun 24

S-8 POS

Registration of securities for employees (post-effective amendment)

30 May 24

S-8 POS

Registration of securities for employees (post-effective amendment)

30 May 24

S-8 POS

Registration of securities for employees (post-effective amendment)

30 May 24

S-8 POS

Registration of securities for employees (post-effective amendment)

30 May 24

POSASR

Automatic shelf registration (post-effective amendment)

30 May 24

8-K

Termination of a Material Definitive Agreement

30 May 24

25-NSE

Exchange delisting

30 May 24

8-K

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

24 May 24

DEFA14A

Additional proxy soliciting materials

20 May 24

8-K

Other Events

17 May 24

DEFA14A

Additional proxy soliciting materials

17 May 24

8-K

Inhibrx Reports First Quarter 2024 Financial Results

9 May 24

8-K

Other Events

8 May 24

DEFM14A

Proxy related to merger

26 Apr 24

DEFA14A

Additional proxy soliciting materials

12 Mar 24

8-K

Other Events

12 Mar 24

8-K

Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results

28 Feb 24

DEFA14A

Additional proxy soliciting materials

6 Feb 24

DEFA14A

Additional proxy soliciting materials

23 Jan 24

DEFA14A

Additional proxy soliciting materials

23 Jan 24

8-K

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

23 Jan 24

8-K

Inhibrx Reports Third Quarter 2023 Financial Results

9 Nov 23

8-K

Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma

2 Nov 23

8-K

Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada

19 Sep 23

D

$200.00 mm in equity / options / securities to be acquired, sold $200.00 mm, 5 investors

31 Aug 23

8-K

Inhibrx Announces $200 Million Private Placement Financing

29 Aug 23

8-K

Inhibrx Reports Second Quarter 2023 Financial Results

7 Aug 23

8-K

Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

30 May 23

8-K

Submission of Matters to a Vote of Security Holders

25 May 23

8-K

Inhibrx Reports First Quarter 2023 Financial Results

8 May 23

8-K

Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials

26 Apr 23

DEFA14A

Additional proxy soliciting materials

13 Apr 23

DEF 14A

Definitive proxy

13 Apr 23

8-K

Regulation FD Disclosure

10 Mar 23

SC 13G/A

VIKING GLOBAL INVESTORS LP

3 Jun 24

4

OLE ANDREAS HALVORSEN

3 Jun 24

4

Inhibrx Biosciences, Inc.

31 May 24

4

Kristiina MD Vuori

30 May 24

4

KIMBERLY MANHARD

30 May 24

4

Mark Lappe

30 May 24

4

Jon Faiz Kayyem

30 May 24

4

DOUGLAS FORSYTH

30 May 24

4

Brendan P. Eckelman

30 May 24

4

Kelly Deck

30 May 24

144

Notice of proposed sale of securities

28 May 24

4

Brendan P. Eckelman

24 May 24

3

Inhibrx Biosciences, Inc.

24 May 24

144

Notice of proposed sale of securities

22 May 24

4

Kelly Deck

8 May 24

144

Notice of proposed sale of securities

6 May 24

4

Kelly Deck

28 Mar 24

144

Notice of proposed sale of securities

26 Mar 24

4

Kelly Deck

22 Mar 24

144

Notice of proposed sale of securities

22 Mar 24

144

Notice of proposed sale of securities

21 Mar 24

144

Notice of proposed sale of securities

20 Mar 24

4

Brendan P. Eckelman

15 Mar 24

4

Kelly Deck

15 Mar 24

144

Notice of proposed sale of securities

13 Mar 24

144

Notice of proposed sale of securities

13 Mar 24

4

Brendan P. Eckelman

12 Mar 24

4

Kelly Deck

12 Mar 24

144

Notice of proposed sale of securities

12 Mar 24

144

Notice of proposed sale of securities

11 Mar 24

144

Notice of proposed sale of securities

8 Mar 24

144

Notice of proposed sale of securities

8 Mar 24

4

Kelly Deck

6 Mar 24

144

Notice of proposed sale of securities

5 Mar 24

144

Notice of proposed sale of securities

4 Mar 24

SC 13G/A

Kayyem Jon Faiz

14 Feb 24

SC 13G/A

RA CAPITAL MANAGEMENT, L.P.

14 Feb 24

SC 13G/A

PERCEPTIVE ADVISORS LLC

14 Feb 24

SC 13G/A

Lappe Mark

14 Feb 24

SC 13G/A

Eckelman Brendan P.

14 Feb 24